Figure 1. Schematic of the transgene insertion of a human BCMA cDNA cassette. Human BCMA gene is controlled by a CMA promoter.
Figure 2. Expression of human BCMA on MC38-hBCMA cells was confirmed by flow cytometry.
MC38-hBCMA cells and wild type MC38 cells were stained with species-specific anti- BCMA antibody. FACS analysis shows that human BCMA expression on MC38-hBCMA cells was approximately 99%.
Figure 3. In vivo tumor growth curves in humanized MC38-hBCMA syngeneic model.
C57BL/6 mice were subcutaneously injected MC38-hBCMA cells compared with wild type MC38 cells as control. Tumor growth was monitored by measuring tumor size from day 6 after subcutaneous implantation.
Data shows that there were no significant differences between MC38-hBCMA cells and wild type MC38 cells in either tumorigenicity or tumor growth.
Figure 4. FACS analysis of BCMA expression on tumor cells derived from humanized MC38-hBCMA syngeneic model with species-specific anti-BCMA antibodies.
FACS analysis shows that human BCMA expression in human BCMA knock-in tumor were approximately 68.14% (low dose) and 70.41% (high dose).
Please fill in the order form and we will contact you within 2 working days.
